vs
ANI PHARMACEUTICALS INC（ANIP）とOSI SYSTEMS INC（OSIS）の財務データ比較。上の社名をクリックして会社を切り替えられます
OSI SYSTEMS INCの直近四半期売上が大きい（$464.1M vs $247.1M、ANI PHARMACEUTICALS INCの約1.9倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 8.3%、差は2.8%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 10.5%）。OSI SYSTEMS INCの直近四半期フリーキャッシュフローが多い（$55.5M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 7.0%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
OSIシステムズ社は米国カリフォルニア州に本社を置く企業で、空港保安用X線検査装置・金属探知機などのセキュリティ検査システム、医療用モニタリング・麻酔システム、光電子デバイスの開発・販売を手がけ、子会社にSpacelabs Healthcare、Rapiscan Systems、OSI Optoelectronicsがあり、全世界で約3180人の従業員を擁する。
ANIP vs OSIS — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $464.1M |
| 純利益 | $27.5M | $38.7M |
| 粗利率 | — | 32.7% |
| 営業利益率 | 14.1% | 12.7% |
| 純利益率 | 11.1% | 8.3% |
| 売上前年比 | 29.6% | 10.5% |
| 純利益前年比 | 367.5% | 2.3% |
| EPS（希薄化後） | $1.14 | $2.22 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $464.1M | ||
| Q3 25 | $227.8M | $384.6M | ||
| Q2 25 | $211.4M | $505.0M | ||
| Q1 25 | $197.1M | $444.4M | ||
| Q4 24 | $190.6M | $419.8M | ||
| Q3 24 | $148.3M | $344.0M | ||
| Q2 24 | $138.0M | $480.9M | ||
| Q1 24 | $137.4M | $405.4M |
| Q4 25 | $27.5M | $38.7M | ||
| Q3 25 | $26.6M | $20.6M | ||
| Q2 25 | $8.5M | $52.7M | ||
| Q1 25 | $15.7M | $41.1M | ||
| Q4 24 | $-10.3M | $37.8M | ||
| Q3 24 | $-24.2M | $17.9M | ||
| Q2 24 | $-2.3M | $44.7M | ||
| Q1 24 | $18.2M | $34.0M |
| Q4 25 | — | 32.7% | ||
| Q3 25 | — | 32.0% | ||
| Q2 25 | — | 33.3% | ||
| Q1 25 | — | 33.8% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | — | 35.3% | ||
| Q2 24 | — | 32.1% | ||
| Q1 24 | — | 33.6% |
| Q4 25 | 14.1% | 12.7% | ||
| Q3 25 | 15.9% | 8.6% | ||
| Q2 25 | 6.6% | 14.5% | ||
| Q1 25 | 13.3% | 12.7% | ||
| Q4 24 | -2.3% | 13.8% | ||
| Q3 24 | -13.8% | 8.8% | ||
| Q2 24 | 3.7% | 13.1% | ||
| Q1 24 | 14.8% | 12.7% |
| Q4 25 | 11.1% | 8.3% | ||
| Q3 25 | 11.7% | 5.3% | ||
| Q2 25 | 4.0% | 10.4% | ||
| Q1 25 | 8.0% | 9.3% | ||
| Q4 24 | -5.4% | 9.0% | ||
| Q3 24 | -16.3% | 5.2% | ||
| Q2 24 | -1.7% | 9.3% | ||
| Q1 24 | 13.2% | 8.4% |
| Q4 25 | $1.14 | $2.22 | ||
| Q3 25 | $1.13 | $1.18 | ||
| Q2 25 | $0.36 | $3.04 | ||
| Q1 25 | $0.69 | $2.40 | ||
| Q4 24 | $-0.45 | $2.22 | ||
| Q3 24 | $-1.27 | $1.05 | ||
| Q2 24 | $-0.14 | $2.57 | ||
| Q1 24 | $0.82 | $1.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $336.7M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $540.7M | $845.5M |
| 総資産 | $1.4B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.19× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $336.7M | ||
| Q3 25 | $262.6M | $124.4M | ||
| Q2 25 | $217.8M | $106.4M | ||
| Q1 25 | $149.8M | $95.8M | ||
| Q4 24 | $144.9M | $101.6M | ||
| Q3 24 | $145.0M | $85.1M | ||
| Q2 24 | $240.1M | $95.4M | ||
| Q1 24 | $228.6M | $101.4M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $442.2M | ||
| Q2 25 | — | $471.6M | ||
| Q1 25 | — | $473.2M | ||
| Q4 24 | — | $474.8M | ||
| Q3 24 | — | $476.3M | ||
| Q2 24 | — | $137.6M | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $845.5M | ||
| Q3 25 | $505.8M | $946.0M | ||
| Q2 25 | $436.8M | $951.1M | ||
| Q1 25 | $418.6M | $879.3M | ||
| Q4 24 | $403.7M | $825.8M | ||
| Q3 24 | $405.9M | $786.5M | ||
| Q2 24 | $455.8M | $863.5M | ||
| Q1 24 | $452.0M | $813.4M |
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.3B | $2.2B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $920.8M | $1.9B | ||
| Q1 24 | $914.5M | $1.8B |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.57× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $62.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $55.5M |
| FCFマージンFCF / 売上 | 11.8% | 12.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.4% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.61× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $137.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $62.2M | ||
| Q3 25 | $44.1M | $17.1M | ||
| Q2 25 | $75.8M | $562.0K | ||
| Q1 25 | $35.0M | $81.6M | ||
| Q4 24 | $15.9M | $52.5M | ||
| Q3 24 | $12.5M | $-37.2M | ||
| Q2 24 | $17.4M | $-29.0M | ||
| Q1 24 | $18.3M | $-52.1M |
| Q4 25 | $29.1M | $55.5M | ||
| Q3 25 | $38.0M | $10.1M | ||
| Q2 25 | $71.8M | $-5.6M | ||
| Q1 25 | $32.5M | $77.1M | ||
| Q4 24 | $13.5M | $47.1M | ||
| Q3 24 | $7.7M | $-44.9M | ||
| Q2 24 | $13.0M | $-37.5M | ||
| Q1 24 | $13.7M | $-57.0M |
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 16.7% | 2.6% | ||
| Q2 25 | 34.0% | -1.1% | ||
| Q1 25 | 16.5% | 17.4% | ||
| Q4 24 | 7.1% | 11.2% | ||
| Q3 24 | 5.2% | -13.0% | ||
| Q2 24 | 9.4% | -7.8% | ||
| Q1 24 | 10.0% | -14.1% |
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 1.8% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 1.3% | 1.3% | ||
| Q3 24 | 3.2% | 2.2% | ||
| Q2 24 | 3.2% | 1.8% | ||
| Q1 24 | 3.3% | 1.2% |
| Q4 25 | 1.10× | 1.61× | ||
| Q3 25 | 1.66× | 0.83× | ||
| Q2 25 | 8.87× | 0.01× | ||
| Q1 25 | 2.23× | 1.98× | ||
| Q4 24 | — | 1.39× | ||
| Q3 24 | — | -2.07× | ||
| Q2 24 | — | -0.65× | ||
| Q1 24 | 1.00× | -1.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OSIS
| Security Division | $334.7M | 72% |
| Optoelectronics And Manufacturing Division | $92.8M | 20% |
| Healthcare Division | $36.5M | 8% |
